Cardiovascular medications frequently lead the polypharmacy category, often contributing to adverse clinical outcomes, and the most vulnerable among us are often prescribed the most complex regimens.

BMI = body mass index; CVD = cardiovascular disease; DM = diabetes mellitus; HDL = high-density lipoprotein; IFN = interferon; NET = neuroendocrine tumor; SLE = systemic lupus erythematosus. The high ...

Secondary prevention medications for cardiovascular diseases (CVD) are underused globally and additional strategies to increase their use are needed to improve CVD management and reduce premature ...

A lower treatment threshold of ≥130/80 mm Hg was associated with reduced postpartum emergency department (ED) visits for a hypertensive disorder of pregnancy (HDOP), according to a study published in ...

In this week’s View, Dr. Eagle looks at cardiac rehabilitation for people with heart failure. He then discusses managing cardiovascular (CV) disease in cancer survivors who have completed cancer ...

Patients with a history of cardiovascular disease, compared with those without, had a higher incidence of sudden cardiac death (SCD), according to a study of 5.5 million Danish citizens in 2010, ...

Among patients with takotsubo syndrome (TTS), beta-blocker therapy was associated with lower follow-up mortality but not lower TTS recurrence, according to a study published Feb. 5 in JACC: Heart ...

Days alive out of health care and hospitalization (DAoH), a novel measure of outcomes in children undergoing cardiovascular surgery, offers advantages over the traditional outcome measure of days ...

Disparities in life expectancy, driven by race, geography, socioeconomic status and systemic inequities, have widened alarmingly – from a 12.6-year gap in 2000 to a staggering 20.4 years by 2021 in ...

Secondary prevention medications for cardiovascular diseases are underused globally and additional strategies to increase their use are needed to improve management and reduce premature mortality ...

Taylor receiving ACC's 2024 Pamela S. Douglas Award for Diversity and Inclusion at ACC.24 in Atlanta, GA. Herman A. Taylor's, MD, FACC, pioneering career in cardiovascular medicine has been ...

The ULTIMATE-DAPT (One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes) trial data demonstrated that, in patients with acute coronary syndrome who underwent percutaneous coronary ...